Biogen (BIIB) Reiterated at Overweight by Cantor Fitzgerald: Advancing with BIIB080
June 22, 2026 7:33 AM
Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating and $206.00 price target on Biogen (NASDAQ: BIIB).The analyst commented, "we ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
